SecBot SecBot
424B5 ·Filed Nov 9, 2026

ZBH

ZIMMER BIOMET HOLDINGS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7d 10h ago SEC0001193125-26-453563
Notable filing: 424B5
Actionable Insight • Neutral

The offering refinances near-term maturities (EUR 500M Dec 2026 and $600M Feb 2027 notes) and extends debt maturity profile. Monitor use of proceeds for debt repayment versus share repurchases or M&A. The concurrent USD notes offering adds $500M of additional debt capacity if completed.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$107.32
T+0 close · Nov 9, 2026 · via day close
Latest settled
+0.14%
T+1 · $107.47 · next T+5 in 4h
Vs SPY
−1.18%
α at T+1
Latest observation
−4.63%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $107.32entry
  2. T+1 · 6d ago +0.14%α −1.18% · $107.47
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zimmer Biomet is issuing EUR 500 million of 4.375% notes due 2033, with net proceeds of approximately EUR 496.4 million (about $556.9 million) to be used for general corporate purposes including potential repayment of near-term maturing debt (EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027). The offering is a debt refinancing and capital management move, announced alongside a concurrent $500M USD notes offering. The company reported Q3 2026 results five days prior with modest revenue growth and raised full-year guidance.

Key Financial Metrics

Offering Size
$560.9M
Underwriters
Barclays Bank PLC, Citigroup Global Markets Limited +12

Key Facts

  • EUR 500,000,000 aggregate principal amount of 4.375% notes due November 12, 2033
  • Net proceeds to issuer approximately EUR 496.4 million (about $556.9 million at EUR/USD 1.1219)
  • Use of proceeds includes general corporate purposes, potential repayment of EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027, share repurchases, and acquisitions
  • Concurrent offering of $500M 5.850% notes due 2036 announced; neither offering conditioned on the other
  • Notes are unsecured, unsubordinated obligations; rank equally with existing unsecured debt
  • Underwriters include Barclays, Citigroup, HSBC, Morgan Stanley, RBC Capital Markets, and others
  • Underwriting discount of 0.400%; proceeds before expenses 99.594% of principal
  • Q3 2026 results (filed Nov 4): net sales $2.063B (+3.1% reported), adjusted EPS $1.90, GAAP EPS $1.00; full-year guidance raised
  • At September 30, 2026, approximately $7.5 billion of consolidated indebtedness outstanding, none subsidiary debt

Financial Impact

EUR 500 million debt issuance; net proceeds ~EUR 496.4 million; concurrent $500M USD notes offering

debtinterest expenseliquidity

Risk Factors

  • Increased total debt and interest expense
  • Euro-denominated notes expose holders to FX risk
  • No established trading market for the notes; listing on NYSE not guaranteed
  • Potential conflict of interest as underwriters may hold existing notes being refinanced

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
32% bullish (31 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-453563
Document: d180022dexfilingfees.htm0001193125-26-453563
Document: 0001193125-26-453563-index-headers.html0001193125-26-453563
Document: 0001193125-26-453563-index.html0001193125-26-453563
Document: 0001193125-26-453563.txt0001193125-26-453563

Track record

17 reports on ZBH

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
  2. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  3. Nov 9, 20267d ago 424B5 Neutral 3/10 Viewing Entry $107.32 Now $101.41 −5.51% settles Nov 17
  4. Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  5. Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
  7. Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
  8. Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
  9. Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
  10. Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026